Literature DB >> 31197649

Obesity and aging affects skeletal muscle renin-angiotensin system and myosin heavy chain proportions in pre-diabetic Zucker rats.

Viktória Lóry1, Lucia Balážová2, Katarína Kršková2, Ľubica Horváthová2, Rafal Olszanecki3, Maciej Suski3, Štefan Zórad2.   

Abstract

There is a gap in the knowledge regarding regulation of local renin-angiotensin system (RAS) in skeletal muscle during development of obesity and insulin resistance in vivo. This study evaluates the obesity- and age-related changes in the expression of local RAS components. Since RAS affects skeletal muscle remodelling, we also evaluated the muscle fibre type composition, defined by myosin heavy chain (MyHC) mRNAs and protein content. Gene expressions were determined by qPCR and/or Western blot analysis in musculus quadriceps of 3- and 8-month-old male obese Zucker rats and their lean controls. The enzymatic activity of aminopeptidase A (APA) was determined flourometrically. Activation of renin receptor (ReR)/promyelocytic leukaemia zinc finger (PLZF) negative feedback mechanism was observed in obesity. The expression of angiotensinogen and AT1 was downregulated by obesity, while neutral endopeptidase and AT2 expressions were upregulated in obese rats with aging. Skeletal muscle APA activity was decreased by obesity, which negatively correlated with the increased plasma APA activity and plasma cholesterol. The expression of angiotensin-converting enzyme (ACE) positively correlated with MyHC mRNAs characteristic for fast-twitch muscle fibres. The obesity- and age-related alterations in the expression of both classical and alternative RAS components suggest an onset of a new equilibrium between ACE/AngII/AT1 and ACE2/Ang1-7/Mas at lower level accompanied by increased renin/ReR/PLZF activation. Increased APA release from the skeletal muscle in obesity might contribute to increased plasma APA activity. There is a link between reduced ACE expression and altered muscle MyHC proportion in obesity and aging.

Entities:  

Keywords:  Age; Angiotensin II; Insulin resistance; Muscle fibre types; Myosin heavy chain; Obesity; Renin–angiotensin system; Skeletal muscle

Mesh:

Substances:

Year:  2019        PMID: 31197649     DOI: 10.1007/s13105-019-00689-1

Source DB:  PubMed          Journal:  J Physiol Biochem        ISSN: 1138-7548            Impact factor:   4.158


  5 in total

1.  Insulin-Regulated Aminopeptidase Inhibition Ameliorates Metabolism in Obese Zucker Rats.

Authors:  Katarina Krskova; Lucia Balazova; Viktoria Dobrocsyova; Rafal Olszanecki; Maciej Suski; Siew Yeen Chai; Štefan Zorad
Journal:  Front Mol Biosci       Date:  2020-12-04

2.  Hypothalamic Renin-Angiotensin System and Lipid Metabolism: Effects of Virgin Olive Oil versus Butter in the Diet.

Authors:  Ana Belén Segarra; Germán Domínguez-Vías; José Redondo; Magdalena Martínez-Cañamero; Manuel Ramírez-Sánchez; Isabel Prieto
Journal:  Nutrients       Date:  2021-01-31       Impact factor: 5.717

3.  Oxidative phenotype induced by aerobic physical training prevents the obesity-linked insulin resistance without changes in gastrocnemius muscle ACE2-Angiotensin(1-7)-Mas axis.

Authors:  Bruno Vecchiatto; Rafael C da Silva; Talita S Higa; Cynthia R Muller; Anna Laura V Américo; Vanessa C Fortunato-Lima; Marília M Ferreira; Luiz Felipe Martucci; Miriam H Fonseca-Alaniz; Fabiana S Evangelista
Journal:  Diabetol Metab Syndr       Date:  2021-07-06       Impact factor: 3.320

Review 4.  Mechanism of increased risk of insulin resistance in aging skeletal muscle.

Authors:  Jian Shou; Pei-Jie Chen; Wei-Hua Xiao
Journal:  Diabetol Metab Syndr       Date:  2020-02-11       Impact factor: 3.320

5.  AVE0991, a Nonpeptide Angiotensin 1-7 Receptor Agonist, Improves Glucose Metabolism in the Skeletal Muscle of Obese Zucker Rats: Possible Involvement of Prooxidant/Antioxidant Mechanisms.

Authors:  Viktoria Dobrocsyova; Miroslava Slamkova; Katarina Krskova; Lucia Balazova; Maciej Suski; Rafal Olszanecki; Sona Cacanyiova; Stefan Zorad
Journal:  Oxid Med Cell Longev       Date:  2020-01-27       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.